WEAVER GREGORY L 4

What Happened
Gregory L. Weaver, Chief Financial Officer of Altimmune, Inc. (ALT), received equity awards on February 26, 2026 consisting of 259,000 derivative shares (stock option award) and 111,000 Restricted Stock Units (RSUs). Both grants show an acquisition price of $0.00 (typical for compensation awards); no cash changed hands. The awards vest over four years under the schedules described in the filing.

Key Details

• Transaction date: 2026-02-26; Form 4 filed 2026-02-27 (timely filing).
• Awards: 259,000 option-based derivative shares (granted at $0.00) and 111,000 RSUs (each RSU converts to one share when vested).
• Vesting (options): 25% vest on Feb 26, 2027; remaining 75% vests in equal monthly installments over the following 36 months, subject to continued service.
• Vesting (RSUs): 25% vest on Feb 26, 2027; remaining RSUs vest in equal annual installments over the next three years; RSUs have no expiration date.
• Shares owned after transaction: not disclosed in the filing.
• No mention of tax withholding, 10b5-1 plan, or immediate sale; these are compensation grants, not open-market purchases or sales.

Context
These awards are compensation-related grants to an executive. Options are rights to acquire shares in the future if and when exercised; RSUs convert to actual shares upon vesting. Such grants are common for executive retention and do not by themselves indicate immediate buying or selling of shares.